Bio path Holdings inc (BPTH) - News Archive

In a notable development for the biopharmaceutical sector, Bio-Path Holdings, Inc. (NASDAQ: BPTH) has announced it has achieved its third pre-clinical milestone in its efforts to advance BP1001-A, a promising treatment...

Navigating New Frontiers: Bio-Path Holdings and the Quest for Innovative Obesity Treatments in Type 2 Diabetes In an era where chronic diseases such as obesity and Type 2 diabetes have reached epidemic proportions, the...

Bio-Path Holdings Advances BP1001-A: A New Prospect for Treating Obesity in Type 2 Diabetes Patients Bio-Path Holdings Inc has announced the commencement of preclinical testing for its new therapeutic candidate, BP1001-...

Bio-Path Holdings Secures $4.0 Million in Recent Private Placement: An Analysis of Their Financial Maneuvers and Market Position Bio-Path Holdings, Inc. (NASDAQ: BPTH), a Houston-based biotechnology company focused on d...

Bio-Path Holdingsn Strategic Capital Raise: A Catalyst for Cancer InnovationIn a notable development for Bio-Path Holdings, Inc. (NASDAQ: BPTH), the biotechnology company announced on October 8, 2024, its entry into def...

Exploring New Frontiers in Obesity TreatmentIn a groundbreaking development, Bio-Path Holdings, Inc. a biotechnology firm renowned for its innovative cancer treatment solutions, announced the initiation of a new therape...

In a promising development for oncology, Bio-Path Holdings, Inc. has reported vital findings from its ongoing Phase 1/1b clinical trial of BP1001-A, a significant candidate for the treatment of advanced solid tumors. Wi...

CSIMarket.com presents an overview of recent updates from Bio-Path Holdings, focusing on their clinical progress and expansion plans in the treatment of various cancer indications. The article highlights the positive re...

Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials IncreasePALM BEACH, Fla., June 17, 2024 - According to a report from Mordor Intelligence, the Acute Myeloid Leukemia (AML) ma...

Bio-Path Holdings recently presented encouraging data from an ongoing phase 2 combination study of Prexigebersen at the European Hematology Association (EHA) Congress. The presentation highlighted positive outcomes from...

Bio-Path Holdings Successfully Closes Private Placement, Bolstering its Cancer Drug Development PortfolioHouston-based biotechnology company, Bio-Path Holdings, Inc. (NASDAQ:BPTH), announced yesterday the completion of...

Bio-Path Holdings Secures Funding through Private Placement, Aims to Bolster Cancer Drug DevelopmentHouston-based biotechnology company, Bio-Path Holdings, Inc., has recently announced a definitive agreement for the iss...

Bio-Path Holdings, a clinical-stage biotechnology company focused on developing RNAi nanoparticle-based therapies for cancer, recently presented positive data from an ongoing Phase 2 combination study of their drug cand...

Bio-Path Holdings Reports Promising Developments in Acute Myeloid Leukemia Therapies at Upcoming EHA Congress: Prexigebersen Interim Success and BP1002 Milestone Bio-Path Holdings Reports Promising Developments in Acute...

Houston-based biotechnology company Bio-Path Holdings, Inc. has recently announced the successful completion of its registered direct offering valued at $1.2 million. The offering, which was priced at-the-market under N...

In a significant development, Bio-Path Holdings, Inc. (NASDAQ: BPTH), a leading biotechnology company specializing in targeted nucleic acid cancer drugs, has recently entered into a definitive agreement with institution...

In the quest for more effective treatments for refractory/relapsed Acute Myeloid Leukemia (AML), Bio-Path Holdings has successfully completed the higher dose second cohort in a groundbreaking Phase 1/1b clinical trial o...

Bio-Path Holdings, a promising cancer therapeutics company, has successfully completed the first dose cohort for its ongoing Phase 1/1b clinical trial of BP1002. This innovative drug, devised to treat refractory/relapse...